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Abstract
Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone mainly produced by bone that acts in the kidney through
FGF receptors and Klotho. Here we investigated whether the kidney was an additional source of FGF23 during renal disease
using a model of type 2 diabetic nephropathy. Renal expression of FGF23 and Klotho was assessed in Zucker diabetic fatty
(ZDF) and control lean rats at 2, 4, 6, 8 months of age. To evaluate whether the renoprotective effect of angiotensin
converting enzyme (ACE) inhibitor in this model was associated with changes in FGF23 and Klotho, ZDF rats received
ramipril from 4, when proteinuric, to 8 months of age. FGF23 mRNA was not detectable in the kidney of lean rats, nor of
ZDF rats at 2 months of age. FGF23 became measurable in the kidney of diabetic rats at 4 months and significantly
increased thereafter. FGF23 protein localized in proximal and distal tubules. Renal Klotho mRNA and protein decreased
during time in ZDF rats. As renal disease progressed, serum phosphate levels increased in parallel with decline of fractional
phosphorus excretion. Ramipril limited proteinuria and renal injury, attenuated renal FGF23 upregulation and ameliorated
Klotho expression. Ramipril normalized serum phosphate levels and tended to increase fractional phosphorus excretion.
These data indicate that during progressive renal disease the kidney is a site of FGF23 production which is limited by ACE
inhibition. Interfering pharmacologically with the delicate balance of FGF23 and phosphorus in diabetes may have
implications in clinics.
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Introduction
Fibroblast growth factor (FGF) 23 is a phosphaturic hormone
produced in response to an increase in phosphorus load or high
levels of calcitriol or parathyroid hormone [1–3]. FGF23 acts by
inducing renal phosphate excretion by kidney proximal tubular
cells through reduction of the expression of type 2a and 2c sodium
phosphate co-transporters (NaPi-2a and NaPi-2c) [4]. FGF23 also
suppresses the production of vitamin D’s active form (1,25-
dihydroxyvitamin D) in the kidney by inhibiting the synthetic
enzyme 1a-hydroxylase, thereby acting as counter-regulatory
hormone for vitamin D [1,5]. The reduction in circulating 1,25-
dihydroxyvitamin D levels by FGF23 contributes to cause negative
phosphate balance through limiting phosphate absorption from
the intestine [6]. FGF23 exerts its intrarenal biological function by
binding to cognate FGF receptors (FGFRs) requiring the presence
of Klotho, a transmembrane protein highly expressed in the
kidney, as a co-receptor [7]. The site of synthesis of FGF23 is
primarily the bone tissue, more specifically osteocytes and
osteoblasts, although FGF23 is also espressed by brain, thymus,
liver, spleen and heart [8–10]. Since the kidney is an important
target of FGF23, and the circulating levels of FGF23 have been
found to increase in association with disease progression and
cardiovascular events in chronic kidney disease and diabetic
nephropathy [1,2,11], we wondered whether the kidney could be a
source of FGF23 during the development of renal disease. Few
data are so far available showing that renal tissue expressed FGF23
at very low level, if any, in normal conditions [8,12,13] and in
uremic rats [8,13,14].
We took advantage of the Zucker diabetic fatty (ZDF) rat model
of human type 2 diabetic nephropathy characterized by obesity,
hyperlipidemia, insulin resistance, progressive renal injury and
cardiac abnormalities [15–18] and evaluated the expression of
FGF23 in the kidney during the course of the disease. We also
investigated whether renoprotective effects of ACE inhibitor in this
model [19] were associated with modulation of renal FGF23 and
Klotho expression.
Methods
Experimental animals
Male ZDF rats (ZDF/Gmi-fa/fa) and aged-matched non-
diabetic lean rats (ZDF/Gmi-fa/+) (Charles River Laboratories
Italia S.r.l., Calco, Italy) were kept on a 12-hour light/dark cycle
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with free access to water. ZDF rats were maintained on Purina
5008 rat chow to accelerate onset of diabetes. Phosphate content
of Purina 5008 diet was similar to that of rat standard diet. Animal
care and treatment were conducted according with institutional
guidelines in compliance with national (Decreto Legislativo n.116,
Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Circolare n.8,
Gazzetta Ufficiale 14 luglio 1994) and international laws and
policies (EEC Council Directive 86/609, OJL358–1, December
1987; Guide for the Care and Use of Laboratory Animals, US
National Research Council, 1996). [19]. Animal studies were
approved by the Institutional Animal Care and Use Committee of
IRCCS – Istituto di Ricerche Farmacologiche Mario Negri. ZDF
(n = 30) and lean (n= 20) rats were studied from 2 months of age.
Starting from 4 months ZDF rats received daily vehicle or ramipril
(1 mg/kg in the drinking water) [19] until 6 or 8 months. Rats
were sacrificed at 2, 4, 6, 8 months of age (n = 5 rats/each group).
Laboratory parameters
Blood glucose was assessed with reflectance meter (OneTouch
UltraEasy, LifeScan, Milan, Italy). Serum cholesterol, triglycer-
ides, BUN, serum and urinary creatinine were measured by a
Cobas Mira autoanalyzer (Roche Diagnostic Systems, Basel,
Switzerland). Serum FGF23 levels were measured by rat FGF23
ELISA kit (Kainos Laboratories, Inc, Tokyo, Japan). Serum and
urinary phosphorus were assessed by autoanalyzer (CX5, Beck-
man Instruments Inc., Fullerton, CA, USA). Fractional excretion
of phosphorus was calculated using the formula: [urine phosphate
x serum creatinine]6100/[serum phosphate x urine creatinine].
The tubular maximum reabsorption of phosphorus per glomerular
filtration rate (TmP/GFR) was calculated using the formula:
serum phosphate -[(urine phosphate x serum creatinine)/urine
creatinine] (mg/dl). Proteinuria was measured by the blue
Coomassie method using a Cobas Mira autoanalyzer. Systolic
blood pressure was evaluated with a computerized tail-cuff system
in conscious rats.
Real time quantitative (q) PCR and reverse-transcriptase
(RT)-PCR
Total RNA was extracted from whole kidney tissue using
TRIzol reagent (Life Technologies, Monza, Italy). Purified RNA
(2 mg) was reverse transcribed. qPCR was performed on 7300
Real-Time PCR System (Life Technologies) using the following
Figure 1. Renal functional parameters and structural changes in ZDF rats, and effect of ACE inhibitor therapy. (a) Serum creatinine, (b)
proteinuria, (c) glomerulosclerosis, (d) tubular damage and (e) interstitial accumulation of ED-1 positive monocytes/macrophages were evaluated
during time in lean rats, and in ZDF rats receiving vehicle or ramipril from 4 to 8 months of age (n = 5 rats each group/time). Values are mean 6 SEM
or median for proteinuria. *p,0.05, **p,0.01 vs age-matched lean rats; #p,0.05, ##p,0.01 vs ZDF+vehicle.
doi:10.1371/journal.pone.0070775.g001
Figure 2. Time course of serum FGF23 levels in lean and ZDF
rats. Serum FGF23 was measured in lean rats, and in ZDF rats receiving
vehicle or ramipril from 4 to 8 months of age (n = 5 rats each group/
time). Values are mean 6 SEM. *p,0.05 vs lean rats at 8 months.
doi:10.1371/journal.pone.0070775.g002
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TaqMan Gene Expression Assays: Rn00590709_m1 for FGF23,
Rn01402172_m1 for Klotho, Rn00564677_m1 for NaPi-2a and
Rn00595128_m1 for NaPi-2c. Rat b-actin endogenous control
(VIC/MGB probe) was used as reference gene. The cDNA
content of each sample was calculated using the DDCt technique.
RT-PCR for FGF23 mRNA expression was performed in Perkin-
Elmer 2700 thermal cycler (Life Technologies) by 35 cycles of
denaturation (94uC, 30 sec), annealing (60uC, 1 min) and
extension (72uC, 1 min). The following primers were used:
forward 59-CCCATCAGACTATCTACAGTGCCC-39; reverse
59-GCTTCGGTGACAGGTAGACGTC-39. The amplification
products were detected on 2% agarose gel and their identity
confirmed by sequencing.
Renal histology
Paraffin-embedded kidney sections (3 mm) were stained with
hematoxylin/eosin and periodic-acid Schiff reagent. The extent of
glomerular damage was expressed as percentage of sclerotic
glomeruli. At least 100 glomeruli were examined for each animal.
Tubular changes (atrophy, dilatation, hyaline casts) were graded
from 0 to 4 (0, no changes; 1, changes affecting 25% of the sample;
2, changes affecting .25–50% of the sample; 3, changes affecting
.50–75% of the sample; 4, changes affecting .75–100% of the
sample). Kidney biopsies were analyzed by the same pathologist,
who was unaware of the nature of the experimental groups.
Immunohistochemistry
Mouse monoclonal anti-rat antibody (1:100, Chemicon, Teme-
cula, CA) was used for the detection of monocyte/macrophage
ED-1 surface antigen by alkaline phosphatase-Fast Red technique
on paraffin-embedded sections. ED-1 positive cells were counted
in 30 randomly selected interstitial high-power microscopic fields
(HPF, 6400) for each animal. FGF23, Klotho and NaPi-2a
proteins were detected by immunoperoxidase 3,3-diaminobenzi-
dine technique with Vectastain ABC kit (Vector Laboratories,
Burlingame, CA) on paraffin-embedded sections using as primary
antibodies: rabbit anti-mouse FGF23 antibody (1:100, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) detecting FGF23 of both
mouse and rat origin or goat anti-human FGF23 antibody (1:200,
Abcam, Cambridge, UK) also detecting rat FGF23 protein [20],
goat anti-human Klotho antibody (1:100, Santa Cruz Biotechnol-
ogy), rabbit anti-human NaPi-2a antibody (1:50, Alpha Diagnos-
tic, San Antonio, TX, USA), followed by biotinylated antibodies.
Nuclei were counterstained with Harris hematoxylin. Negative
controls were obtained by omitting the primary antibody on
adjacent sections.
Western blot analysis
Frozen kidney tissues were homogenized in lysis buffer (50 mM
Tris-HCl (pH 8), 150 mM NaCl, 1% Triton X-100, 0.5% Sodium
deoxycholate, 0.1% SDS) containing the Halt protease inhibitor
cocktail (Thermo Scientific, Rockford, IL, USA). Protein concen-
tration was determined using the bicinchoninic acid assay
(Thermo Scientific) following the manufacturer’s instructions.
The samples (50 mg) were resolved on 10% SDS-polyacrylamide
gel and transferred to nitrocellulose membranes. After blocking,
the blots were incubated with rabbit anti-human NaPi-2a antibody
(1:200, Alpha Diagnostic) or mouse monoclonal anti-a-tubulin
antibody (1:4000; Sigma-Aldrich, St Louis, MO, USA) overnight
at 4uC and with an appropriate secondary antibody linked to
horseradish peroxidase (Sigma-Aldrich). Protein bands were
detected by Supersignal chemiluminescent substrate (Thermo
Scientific) and quantified using NIH Image J Software. The
amount of NaPi-2a protein was calculated relative to the level of a-
tubulin.
Statistical analysis
Results are mean 6 SEM. Serum triglycerides and proteinuria
data that are not normally distributed are expressed as median and
interquartile range (IQR). Data were analyzed using ANOVA
coupled with Bonferroni post hoc analysis or non-parametric
Mann-Whitney or Kruskal-Wallis test for multiple comparisons, as
appropriate. The degree of association between renal FGF23
expression and renal damage markers was assessed by calculating
non parametric Spearman’s rho coefficient. Statistical significance
level was defined as p,0.05.
Results
Characteristics of the type 2 diabetes model of ZDF rats
Food intake was significantly higher in ZDF rats with respect to
lean rats during the whole study period (2 months: 2462 vs
1761 g/day, p,0.05; 4 months: 3061 vs 1661 g/day, p,0.01;
6 months: 2962 vs 1761 g/day, p,0.01; 8 months: 2761 vs
1761 g/day, p,0.01). ZDF rats exhibited hyperglycemia, abnor-
mal lipid profile, mild hypertension and increased BUN and serum
creatinine levels with respect to lean rats (Table 1 and Fig. 1a), in
line with previous observations [19]. As shown in Fig. 1b,
proteinuria progressively increased during time reaching at
8 months of age 385 mg/day (median; IQR: 330–531, vs lean
rats: 16 (14–20) mg/day). By 6 months, ZDF rats developed
glomerulosclerosis that became more severe at 8 months affecting
on average 2262% of glomeruli (Fig. 1c). Tubular damage
consisting of atrophy, dilatation and hyaline casts, and interstitial
inflammation, evaluated as accumulation of ED1-positive mono-
cytes/macrophages, were also present and worsened during the
disease (Fig. 1d and e). The time course of serum levels of FGF23
is reported in Fig. 2. Levels were significantly (p,0.05) increased in
ZDF rats with respect to lean rats at 8 months.
Table 1. Systemic and laboratory parameters in lean and ZDF rats at 8 months of age.
Groups
Body
weight (g)
Food Intake
(g/day)
Blood Glucose
(mg/dl)
Serum Cholesterol
(mg/dl)
Serum triglycerides
(mg/dl)
Blood pressure
(mmHg)
BUN
(mg/dl)
Lean 44469 1761 11062 11565 146 (124–204) 13963 2762
ZDF+vehicle 391614* 2761** 506622** 369625** 1420 (929–1592) ** 14563 4265*
ZDF+ramipril 38768** 2963** 51369** 284615**,# 824 (775–932)** 12165*,## 3364
Values are mean 6 SEM or median (IQR). *p,0.05, **p,0.01 vs lean; #p,0.05, ##p,0.01 vs ZDF+vehicle.
doi:10.1371/journal.pone.0070775.t001
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Figure 3. Renal expression of FGF23 and Klotho during the course of the disease of ZDF rats, and modulation by ACE inhibitor
therapy. (a) FGF23 mRNA expression evaluated in kidney tissue from lean and ZDF rats at different ages, and effect of ACE inhibitor treatment (n = 5
rats each group/time). FGF23 mRNA was not detectable in the kidneys of lean rats at all times period nor in ZDF rats at 2 months of age; it was
measurable in the kidney of 4-month old ZDF rats. Relative expression values were calculated by the DDCt method using the cDNA expression of ZDF
Kidney as Source of FGF23 in Experimental Diabetes
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FGF23 and Klotho expression in the kidney of ZDF rats
The expression of FGF23 mRNA was evaluated in the kidney of
lean and ZDF rats at 2, 4, 6, 8 months of age by either qPCR
(Fig. 3a) or RT-PCR (Fig. S1). FGF23 mRNA was not detectable
in the kidney of lean rats at all the time points nor in the kidney of
ZDF rats at 2 months, but became measurable at 4 months and
further increased thereafter. By immunohistochemistry, using two
different anti-FGF23 antibodies, no FGF23 signal was found in
lean or ZDF rats at 2 months of age (not shown), whereas focal
staining of FGF23 was present in both proximal and distal tubular
profiles at a more advanced phase of the disease (Fig. 3b).
Concomitant to renal FGF23 overexpression, renal Klotho
mRNA levels and protein staining, observed in distal tubules,
decreased during time in ZDF rats with respect to lean rats (Fig. 3c
and d).
Renal expression of sodium phosphate co-transporters
and phosphate metabolism in ZDF rats
Since FGF23 down-regulates the expression of sodium phos-
phate co-transporters in the proximal tubules, thereby diminishing
phosphate reabsorption and increasing urinary phosphate excre-
tion [1–3], we evaluated the expression of NaPi-2a and NaPi-2c in
the kidney of ZDF rats during the course of the disease. NaPi-2a is
the protein mainly responsible for phosphate reabsorption in the
kidney [21]. NaPi-2a mRNA was normally expressed at 4 months
of age but significantly reduced at 6 and 8 months in diabetic rats
with respect to controls (Fig. 4a). Western blot analysis showed a
significant decrease of NaPi-2a protein expression in the kidney of
ZDF rats at 8 months of age versus lean rats (Fig. 4b). These
results were confirmed by immunohistochemistry analysis showing
a reduced staining for NaPi-2a protein at the brush border
membrane of proximal tubules of ZDF rats (Fig. 4c). NaPi-2c
mRNA expression was slightly but not significantly decreased in
the kidney of ZDF rats at 8 months (21% reduction versus lean
rats) (not shown).
Serum phosphate levels of ZDF rats were not different from
those of lean rats until 6 months of age. A significant increase
(p,0.05 versus lean rats) was found at 8 months (Fig. 5a). Urinary
total phosphorus (Fig. 5b) and fractional excretion of phosphorus
(Fig. 5c) were similar in ZDF and lean rats at 2 months. Increased
levels of urinary phosphorus excretion were found in ZDF rats at
4 months, that persisted subsequently (Fig. 5b). Fractional
phosphorus excretion, which was elevated at 4 months, showed
a tendency to decline during the course of the disease as a
consequence of renal function impairment (Fig. 5c). As shown in
Fig. 5d, the ratio of the maximum rate of tubular phosphate
reabsorption to the GFR (TmP/GFR) -which is referred to as the
theoretical renal phosphate threshold- in ZDF rats given vehicle
showed with time from 4 to 8 months a tendency to increase
possibly reflecting the decrease in renal function.
Effects of ACE inhibitor treatment in ZDF rats
To study whether renal FGF23 and Klotho expression could be
modulated by ACE inhibitor, ZDF rats received ramipril from
4 months of age, a time point at which animals had developed
proteinuria and signs of renal injury, up to 6 or 8 months.
Accordingly to our previous study [19] ramipril limited dyslipide-
mia, reduced systolic blood pressure, and partially decreased BUN
in ZDF rats (Table 1). Body weight and food intake were not
affected by the treatment (Table 1). The time course of serum
creatinine showed that ramipril prevented the worsening of renal
function. Thus, serum creatinine levels at 6 and 8 months were
similar to those measured at 4 months before the institution of
treatment (Fig. 1a). ACE inhibitor therapy showed in this model a
significant (p,0.01) antiproteinuric effect reaching 55% reduction
of proteinuria versus vehicle at 8 months (median, 195; IQR: 133–
237 mg/day) (Fig. 1b). Glomerular and tubular changes, and
interstitial inflammation were also significantly attenuated (Fig. 1c,
d and e). Ramipril did not affect serum FGF23 levels (Fig. 2). In
the kidney of ZDF rats treated with ramipril, FGF23 mRNA
expression was significantly reduced with respect to animals given
vehicle, but not abrogated (Fig. 3a). In contrast, renal Klotho
mRNA increased to levels near to controls (Fig. 3c). Ramipril
restored renal mRNA expression of NaPi-2a at 8 months (Fig. 4a).
At variance, protein expression was slightly, although not
significantly increased by ACE inhibitor treatment, as shown
either by Western blot or immunohistochemistry (Fig. 4b and c).
Ramipril kept serum phosphate levels of ZDF rats similar to those
of lean rats at 6 and 8 months, as shown in Fig. 5a. Urinary
phosphorus and fractional phosphorus excretion were not
significantly modified after ramipril, although a trend to increase
was observed with respect to vehicle (Fig. 5b and c). Conversely,
TmP/GFR showed a decrease (Fig. 5d).
Correlation analysis
Spearman’s rho rank correlation analysis showed a significant
(p,0.0001) positive correlation between the level of renal FGF23
expression and proteinuria (rho= 0.689), glomerulosclerosis
(rho= 0.823), tubular damage (rho= 0.787) and interstitial ED1-
positive monocytes/macrophages (rho= 0.730). Renal FGF23 also
significantly (p,0.01) correlated positively with fractional phos-
phorus excretion (rho= 0.566) and negatively with NaPi-2a co-
transporter mRNA expression (rho: 20.488).
Discussion
The present study shows that the kidney of ZDF rats, a model
resembling human type 2 diabetic nephropathy, expressed FGF23
starting from the age of 4 months when rats have already
significant levels of proteinuria and signs of renal injury. FGF23
mRNA expression further increased with time as diabetic disease
progressed, reaching levels that were 3–4 times higher than at
4 months. To our knowledge this is the first evidence of FGF23
production by the kidney during renal disease progression.
Upregulation of FGF23 mRNA resulted in the expression of the
corresponding protein localized at proximal and distal tubules in
focal areas of the kidney. A previous study by Mirams et al
[8,12,13] that analyzed FGF23 mRNA expression in several
human tissues showed that FGF23 was detectable in kidney tissue
at low levels. Actually, the highest expression was found in bone
followed by kidney medulla, liver, thyroid and kidney cortex.
at 4 months as reference. Data are mean 6 SEM. *p,0.05, **p,0.01 vs ZDF rats at 4 months; #p,0.05, ##p,0.01 vs ZDF+vehicle rats at
corresponding age. (b) Representative images of FGF23 staining in the kidney of lean rats and ZDF rats receiving vehicle or ramipril at 8 months of
age. FGF23 expression was detected by immunoperoxidase technique using two different anti-FGF23 antibodies (from Santa Cruz Biotechnology, SC,
or Abcam, see Methods). Magnification,6400. (c) Time course of Klotho mRNA expression in the kidney of lean rats and ZDF rats given vehicle or
ramipril (n = 5 rats each group/time). Relative expression values in each group were calculated vs lean rats of corresponding age. Data are mean 6
SEM. *p,0.05 vs lean rats. (d) Representative images of Klotho staining by immunohistochemistry in the kidney of lean rats and ZDF rats treated with
vehicle or ramipril, at 8 months of age. Magnification,6400.
doi:10.1371/journal.pone.0070775.g003
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FGF23 bone expression was approximately 30 times higher than
renal expression in normal conditions, but no data are available
that compared tissues from patients with renal disease. The
prevailing paradigm proposes the bone as the main tissue that
senses changes in phosphate balance and produces FGF23 [3].
The present data would add the kidney as a direct sensor organ
that may interfere in phosphate homeostasis via its own FGF23
production. It is noteworthy that the FGF23 co-receptor Klotho is
expressed weakly in the proximal tubules -despite the fact that the
FGF23 phosphaturic action is substantially exerted at this level-
whereas distal tubules showed more abundant Klotho expression
[22] [23]. Two mechanisms have been proposed [6]: either FGF23
acts on proximal tubules via FGFR-Klotho signaling to directly
regulate NaPi co-transporters, and/or acts on the distal tubules to
induce a paracrine signal to proximal tubules [24]. The putative
paracrine factor is the secreted Klotho itself able to directly inhibit
NaPi co-transporters and to activate several ion channels in
proximal tubules [22]. The significance of the local production of
FGF23 is obscure. FGF23 expression might represent an adaptive
response to early injury as a mechanism by which the ZDF rat
kidney could maintain phosphate homeostasis. Indeed, at
4 months, Klotho was normally expressed in the kidney allowing
FGF23 phosphaturic activity to maintain serum phosphate levels
similar to those of lean rats. Finding that ZDF rats exhibited a 2-
fold higher urinary phosphorus excretion than lean rats could also
be attributed to a 2-fold increased food intake in ZDF rats. As
renal disease progressed, despite the increasing FGF23 levels,
fractional phosphorus excretion decreased possibly due to a lower
renal Klotho expression and a reduction in functioning nephrons,
with the net result of increased serum phosphate levels. Our
finding of decreased Klotho expression in the kidney of ZDF rats
during overt nephropathy is in agreement with findings of decline
of renal Klotho both in rodent models of chronic renal damage
and patients with CKD [22,25]. Klotho is a putative aging
suppressor [26], and there is compelling evidence that its depletion
is associated with oxidative stress, inflammation, accelerated aging
and renal fibrosis [27,28].
An important observation of the present study is that ramipril
therapy, which limited proteinuria and renal damage in ZDF rats,
effectively prevented the time-dependent increase of renal FGF23
expression, and almost normalized Klotho expression. A cross talk
between the renin-angiotensin-system (RAS) and Klotho-FGF23
axis has been suggested (see for a review de Borst et al. [29]).
Angiotensin II causes renal Klotho loss leading to disrupted FGF23
signaling and reduced phosphaturia [29,30]. In a model of renal
damage characterized by renal RAS activation and Klotho
downregulation, the treatment with an angiotensin II type 1
receptor blocker prevented the loss of Klotho expression and
ameliorated renal histology [31]. Here, ramipril by recovering renal
Klotho expression allowed re-engagement of serum and residual
renal FGF23 to exert phosphaturic activity, resulting in normaliza-
tion of serum phosphate levels in diabetic rats. Ramipril was capable
to restore the mRNA expression of NaPi-2a co-transporter to
normal levels, which however, did not translate into recovery of the
protein on the brush border of proximal tubules. Discrepancy
between NaPi-2a co-transporter mRNA and protein expression
could be attributable to post-transcriptional events that precluded a
full restoration of the protein. This would explain the high level of
phosphorus excretion at 8 months in ramipril-treated diabetic rats.
Figure 4. Renal expression of sodium phosphate (NaPi)-2a co-
transporter in ZDF rats, and effect of ramipril. (a) mRNA
expression of NaPi-2a co-transporter evaluated in the kidney of lean
rats, and ZDF rats treated with vehicle or ramipril from 4 to 8 months of
age (n = 5 rats each group/time). Relative expression values were
calculated versus lean rats of corresponding age. Data are mean6 SEM.
*p,0.05 vs age-matched lean rats; #p,0.01 vs ZDF+vehicle. (b)
Western blot analysis for NaPi-2a protein expression, relative to a-
tubulin, in lean rats and ZDF rats treated with vehicle or ramipril, at
8 months of age (n = 5 rats each group). Data are mean 6 SEM.
**p,0.01 vs lean rats. (c) Representative images of NaPi-2a staining by
immunohistochemistry in the kidney of lean rats, and ZDF rats receiving
vehicle or ramipril, at 8 months of age. Magnification,6400.
doi:10.1371/journal.pone.0070775.g004
Kidney as Source of FGF23 in Experimental Diabetes
PLOS ONE | www.plosone.org 6 August 2013 | Volume 8 | Issue 8 | e70775
ACE inhibitor treatment significantly but not completely restored
renal function and structure in the ZDF rats [19].
In early stage of CKD, elevation of FGF23 represents an
appropriate physiological response to prevent hyperphosphatemia.
However, with CKD progression, the excess of biologically active
FGF23 becomes no longer protective and may instead lead to
pathological off-target effects [3]. Elevated circulating levels of
FGF23 were associated with vascular dysfunction, atherosclerotic
burden and left ventricular hyperthrophy in CKD patients
[32,33], and FGF23 directly induced hypertrophy of cultured
cardiomyocytes [9]. Recently, inflammation has been identified as
another potential off-target, in that higher FGF23 levels were
independently associated with higher levels of inflammatory
markers in patients with CKD [34]. Consistently, here, in ZDF
rats the reduction of renal FGF23 production after treatment with
ACE inhibitor was paralleled by less infiltrates of inflammatory
cells in the renal interstitium. To maximize renoprotection in ZDF
rats one could foresee adding other compounds to the ACE
inhibitor. In the search for an effective therapy, molecules that
have the ability to limit, but not to abrogate FGF23 production
would represent a valuable approach. A recent study has shown
vascular calcification associated with increased risk of mortality in
CKD rats after FGF23 neutralization by chronic treatment with a
FGF23 antibody [35], suggesting the importance of maintaining
physiological levels of circulating FGF23.
Findings that in ZDF rats proteinuria preceded FGF23
upregulation in the kidney and that the antiproteinuric effect of
ACE inhibitor was associated with reduced FGF23 expression,
could be taken to suggest proteinuria as a potential trigger of renal
FGF23. Future studies are needed to address this possibility. In this
context, a recent study demonstrated that in patients with CKD
FGF23 was positively associated with proteinuria [36]. Consis-
tenly, we have documented here a positive correlation between
renal FGF23 expression and proteinuria in diabetic rats.
In conclusion, our data indicate that in experimental type 2
diabetes 1. the kidney is a site of FGF23 production; 2. during the
progression of the disease, renal FGF23 increased in the face of
Klotho and NaPi-2a co-transporter reduction; 3. ACE inhibitor
therapy besides exhibiting antiproteinuric and renoprotective
actions, attenuated FGF23 renal production and preserved the
expression of Klotho resulting in sustained improvement of
phosphate homeostasis. These data may offer new clues to
understand how to interfere with the delicate balance of FGF23
and phosphorus in diabetes with potential implications in clinics.
Supporting Information
Figure S1 FGF23 mRNA expression evaluated by RT-
PCR in kidney tissue from lean rats, and ZDF rats
treated with vehicle or ramipril from 4 months of age.
Spleen, a known source of FGF23, was obtained from a control
rat.
(TIFF)
Figure 5. Serum phosphate levels, urinary phosphorus excre-
tion and fractional phosphorus excretion during the course of
the disease in ZDF rats, and effect of ACE inhibitor therapy. (a)
Serum phosphate levels, (b) urinary phosphorus (P), (c) fractional P
excretion and (d) TmP/GFR were measured over time in lean rats, and
ZDF rats given vehicle or ramipril (n = 5 rats each group). Data are mean
6 SEM. *p,0.05, **p,0.01, ***p,0.001 vs age-matched lean rats;
#p,0.05 vs ZDF+vehicle.
doi:10.1371/journal.pone.0070775.g005
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